Logo

NIPD Firm KellBenX Raises $10M in Series C Round

Jul 30, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Non-invasive prenatal diagnostics firm KellBenX has closed on a $10 million Series C financing round, its Co-Founder and CEO Hassan Bennani GenomeWeb Daily News today.

The financing was raised by a new investor that Bennani declined to identify, and will be used to accelerate clinical trials for its technology. Since its inception, it has raised $15 million.

The Great River, NY-based company, founded in 2010, is building a blood-based assay that can separate rare fetal cells in maternal blood. Its technology is based on antibody called 4B9 licensed from AdnaGen. 4B9 recognizes and binds to an epitope expressed by a type of nucleated fetal nucleated red blood cell, or fNRBC.

KellBenX plans to launch its test in late 2014 or early 2015.

Filed under

Diagnostics
Disease Research
Business News
financing
aneuploidy
FISH
KellBenx
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.